Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,569,196
  • Shares Outstanding, K 984,965
  • Annual Sales, $ 14,750 K
  • Annual Income, $ -413,560 K
  • EBIT $ -261 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.16
  • Price/Sales 90.21
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 153.86% (+4.28%)
  • Historical Volatility 176.34%
  • IV Percentile 97%
  • IV Rank 69.84%
  • IV High 192.15% on 04/17/25
  • IV Low 65.20% on 12/30/25
  • Expected Move (DTE 26) 2.59 (29.80%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 93,889
  • Volume Avg (30-Day) 53,386
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 674,745
  • Open Int (30-Day) 557,136
  • Expected Range 6.11 to 11.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.54 +57.04%
on 01/28/26
9.25 -5.95%
on 02/20/26
+2.22 (+34.26%)
since 01/20/26
3-Month
1.95 +346.15%
on 12/31/25
9.25 -5.95%
on 02/20/26
+6.68 (+330.69%)
since 11/20/25
52-Week
1.83 +375.41%
on 05/07/25
9.25 -5.95%
on 02/20/26
+5.06 (+139.01%)
since 02/20/25

Most Recent Stories

More News
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom...

IBRX : 8.70 (+1.05%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised...

IBRX : 8.70 (+1.05%)
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries Dublin-based subsidiary to support ImmunityBio’s distribution...

IBRX : 8.70 (+1.05%)
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),...

IBRX : 8.70 (+1.05%)
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

Saudi FDA (SFDA) Encouraged Company to Submit Regulatory File for Recombinant BCG and Discussions Initiated for the Expansion of ANKTIVA ® in Combination with Checkpoint Inhibitors...

IBRX : 8.70 (+1.05%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX).  Such investors are...

IBRX : 8.70 (+1.05%)
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA ® and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL),...

IBRX : 8.70 (+1.05%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc.  ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised...

IBRX : 8.70 (+1.05%)
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026 Fourteen patients have...

IBRX : 8.70 (+1.05%)
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA for...

IBRX : 8.70 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 10.12
2nd Resistance Point 9.69
1st Resistance Point 9.19
Last Price 8.70
1st Support Level 8.26
2nd Support Level 7.83
3rd Support Level 7.33

See More

52-Week High 9.25
Last Price 8.70
Fibonacci 61.8% 6.42
Fibonacci 50% 5.54
Fibonacci 38.2% 4.66
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar